SciSparc Ltd. (SPRC)
Automate Your Wheel Strategy on SPRC
With Tiblio's Option Bot, you can configure your own wheel strategy including SPRC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SPRC
- Rev/Share 0.645
- Book/Share 4.415
- PB 0.4246
- Debt/Equity 0.0056
- CurrentRatio 5.3631
- ROIC -0.8127
- MktCap 890144.0
- FreeCF/Share -2.5209
- PFCF -0.1744
- PE -0.551
- Debt/Assets 0.0044
- DivYield 0
- ROE -0.8338
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company
Published: December 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
TEL AVIV, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, in which SciSparc holds a controlling interest of approximately 75%, has entered into a non-binding term sheet (the “Term Sheet”) with an Israeli-based pioneering quantum computing bio data company focused on quantum-enabled clinical analytics (the “Target Company"). Pursuant to the Term Sheet, NeuroThera will acquire a 55% equity interest in the Target Company from certain selling shareholders of the Target Company …
Read More
Scisparc Ltd. - Early Warning Regarding Acquisition Of Common Shares Of Neurothera Labs Inc.
Published: October 22, 2025 by: TheNewswire
Sentiment: Neutral
This press release is issued pursuant to National Instrument 62-104 – Take-Over Bids and Issuer Bids and National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues . Vancouver, British Columbia – October 22, 2025 – TheNewswire - Pursuant to the requirements of applicable securities laws, SciSparc Ltd. (“ SciSparc ”) , a corporation incorporated under the laws of the State of Israel and listed on the NASDAQ under the trading symbol “SPRC” with an office address of 20 Raul Wallenberg Street, Tower A, 2nd Floor, Tel Aviv, 6971916, Israel, reports that on October …
Read More
SciSparc: AutoMax's Shareholders Approve Merger with SciSparc
Published: August 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
TEL AVIV, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that AutoMax Motors Ltd. ("AutoMax"), a leading parallel vehicle importer in Israel, convened today its special general meetings, at which, among others, AutoMax's shareholders voted on and approved the proposed merger with SciSparc. In addition, on August 26, 2025, SciSparc's shareholders voted on and approved at an adjourned special general meeting, among others, the proposed merger.
Read More
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
Published: July 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
TEL AVIV, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind”) has led to the filing of a new international patent application under the Patent Cooperation Treaty. The application covers its innovative combination therapy of 5-methoxy-2-aminoindane and N-Acylethanolamines (MEAI) and Palmitoylethanolamide (PEA).
Read More
SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
TEL AVIV, Israel, Feb. 27, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that it has entered into a loan agreement with AutoMax Motors Ltd. ("AutoMax") to provide a $2 million loan (the “New Loan”). The funding will support AutoMax's business expansion following its entry into the direct import of Anhui Jianghuai Automobile Group Corp., Ltd. (“JAC”) electric vehicles. The New Loan is in addition to previous bridge loans in an aggregate amount of $4.25 …
Read More
About SciSparc Ltd. (SPRC)
- IPO Date 2021-08-30
- Website https://scisparc.com
- Industry Biotechnology
- CEO Oz Adler
- Employees 2